What is the purpose of the SIGNAL-HF trial?
The purpose of the SIGNAL-HF trial is to evaluate the efficacy of a monitoring strategy involving the use of natriuretic peptides (NP) in treatment-increased patients with chronic heart failure (CHF). The trial compares two monitoring strategies, one in which treatment is increased to achieve a target NT-proBNP reduction of 50% from baseline and one in which treatment is increased according to clinician's discretion. The trial will assess the effectiveness of the two strategies by measuring mortality outcomes in participants with an average age of 78 years, NYHA class II-IV, and LVEF < 50% who are recruited from primary care settings.  